Publications by authors named "ChangMin Choi"
Article Synopsis
- - Non-small cell lung cancer (NSCLC) is categorized into two main types: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC), but some tumors display mixed characteristics that may be influenced more by other factors than histology alone.
- - A study using data from 691 patients identified five molecular subtypes of NSCLC, including one associated with the PI3K-Akt pathway that correlates with high rates of metastasis and poor survival, regardless of the specific type of NSCLC.
- - The research highlights the immune microenvironment's role, revealing different immune cell compositions and neoantigen levels across subtypes, which can help predict patient outcomes; immunological subtypes showed better responses to
Article Synopsis
- - The study investigates the relationship between the COPD Assessment Test (CAT) scores and postoperative pulmonary complications (PPCs) in patients with mild to moderate COPD undergoing lung surgery, highlighting the necessity of thorough preoperative evaluations.
- - Out of 83 patients analyzed, 19.2% experienced PPCs, with a notable correlation found between higher CAT scores and increased risk of complications; specifically, a CAT score of ≥7 was identified as a significant predictor.
- - The findings suggest that CAT scores can serve as an effective tool for predicting the likelihood of PPCs in COPD patients prior to lung resection surgery, outperforming other traditional predictive factors in this context.
Introduction: Electromagnetic navigation bronchoscopy (ENB) and radial probe endobronchial ultrasound (RP-EBUS) are essential bronchoscopic procedures for diagnosing peripheral lung lesions. Despite their individual advantages, the optimal circumstances for their combination remain uncertain.
Methods: This single-center retrospective study enrolled 473 patients with 529 pulmonary nodules who underwent ENB and/or RP-EBUS biopsies between December 2021 and December 2022.
Article Synopsis
- This study evaluated the effectiveness of local ablative therapy (LAT) combined with pembrolizumab in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC), aiming to identify those who would most benefit from this treatment.
- Out of 258 patients studied, those who underwent LAT along with pembrolizumab experienced significantly improved progression-free survival (PFS) and overall survival (OS) compared to those who received pembrolizumab alone.
- The research also developed a model to categorize patients into risk groups, finding that LAT specifically benefited low- and intermediate-risk patients, while having less impact on high-risk patients.
Article Synopsis
- - The REST trial aims to assess the safety and effectiveness of remimazolam for moderate sedation during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), comparing it against standard midazolam treatments.
- - The study will enroll 330 patients with suspected lung cancer lesions across four university hospitals, randomly assigning them to receive either remimazolam or two types of midazolam for the procedure.
- - Through this trial, researchers hope to establish improved sedation practices for EBUS-TBNA, potentially enhancing patient experiences and outcomes.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are increasingly used to treat advanced lung cancer, but it’s challenging to predict their effectiveness in clinical practice.
- This study analyzed blood cell characteristics in patients with advanced nonsmall cell lung cancer (NSCLC) treated with ICIs to develop a scoring system, known as the Immune Checkpoint Inhibitor Score (IChIS).
- Findings showed that patients with a lower IChIS had significantly longer progression-free and overall survival, suggesting IChIS could be a valuable biomarker for predicting treatment outcomes in NSCLC.
Article Synopsis
- Researchers evaluated the safety and effectiveness of SNK01, a treatment using natural killer cells, alongside chemotherapy and cetuximab for patients with EGFR-mutated non-small cell lung cancer who showed resistance to osimertinib.
- In a mouse model and a clinical trial with 12 patients, results indicated that SNK01 boosted NK cell activity and reduced tumor size, with the best outcomes observed in combination treatments.
- The clinical study showed promising results with a 25% response rate and a median progression-free survival of 143 days, suggesting that SNK01 could be a safe and effective option for this difficult-to-treat cancer population.
Background: Lung cancer (LC) is an important comorbidity of interstitial lung disease (ILD) and has a poor prognosis. The clinical characteristics and outcome of each ILD subtype in LC patients have not been sufficiently investigated. Therefore, this study aimed to evaluate the difference between idiopathic pulmonary fibrosis (IPF) and non-IPF ILD as well as prognostic factors in patients with ILD-LC.
View Article and Find Full Text PDFArticle Synopsis
- - Cyclophilin B (CypB) is linked to important biological processes like immune response and cell growth, and recent research indicates its role in cancer progression and drug resistance, especially in non-small cell lung cancer (NSCLC).
- - A study analyzed PPIB (the gene encoding CypB) expression in 431 NSCLC samples and found that high PPIB levels in adenocarcinomas were associated with worse outcomes, including lymph node metastasis, advanced disease stages, and higher mortality rates.
- - The combination of high PPIB and Ki-67 (a marker for cell proliferation) was identified as a significant predictor of poor survival in adenocarcinomas, highlighting the potential role of
Article Synopsis
- The study investigates the effectiveness of crizotinib for treating ROS1-rearranged non-small-cell lung cancer (NSCLC) in a real-world setting in South Korea, enrolling 40 patients with a median age of 61, many of whom had brain metastases.* -
- Results showed a 70% objective response rate, with patients experiencing a median progression-free survival of 24.1 months and a median treatment duration of 27.8 months; however, 90% reported adverse events, mostly manageable.* -
- Liquid biopsies using next-generation sequencing revealed mutations and resistance mechanisms, supporting crizotinib's efficacy and safety and highlighting the importance of personalized treatment approaches based on emerging genetic changes.*
Purpose: This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
Materials And Methods: In this open-label, single-arm, dose-escalating, multicenter three-part phase 1/2a trial, patients had advanced solid tumors refractory to conventional therapy. Part 1 evaluated the safety and pharmacokinetics of five ascending once-daily doses of rivoceranib from 81 mg to 685 mg.
Article Synopsis
- COVID-19 has put a significant strain on global healthcare systems, highlighting the need for effective resource allocation based on disease severity predictions.
- A study tested machine learning models, including deep neural networks and tree-based models, using data from nearly 4,000 COVID-19 patients to forecast the severity of illness up to two days in advance.
- The deep neural network achieved 91.8% accuracy, but tree-based models slightly outperformed it, each providing valuable insights for treatment prioritization while suggesting that DNNs can be more generalizable across different hospital settings.
Article Synopsis
- This study investigated the effects of adding durvalumab, an immunotherapy drug, to treatment in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) who had already received concurrent chemoradiotherapy (CCRT).
- Results showed that patients receiving durvalumab after CCRT had significantly improved progression-free survival (20.9 months vs. 13.7 months) and better local control rates (57.3% vs. 38.8%) than those who only received CCRT.
- The findings indicate that durvalumab is beneficial in extending survival and controlling disease in LA-NSCLC patients, particularly for those expressing the PD-L1 biomarker, thus supporting its inclusion in standard
Background: About 3%-5% of non-small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK-positive NSCLC. This study aimed to analyze the real-world efficacy and outcome when administered crizotinib, the first approved target agent for ALK-positive NSCLC, according to first- or late-line treatment.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates sex differences in adverse events (AEs) from chemotherapy, focusing on how these differences affect healthcare use and treatment outcomes in female patients.
- Results show that women experienced more frequent and severe AEs like nausea and neutropenia, leading to lower chemotherapy dose intensity and more dose reductions than men.
- The findings highlight the need for physicians to consider gender-specific responses to chemotherapy when making treatment decisions.
Purpose: The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings.
View Article and Find Full Text PDFPurpose: Circulating cell-free DNA (cfDNA) has great potential in clinical oncology. The prognostic and predictive values of cfDNA in non-small cell lung cancer (NSCLC) have been reported, with epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in tumor-derived cfDNAs acting as biomarkers during the early stages of tumor progression and recurrence. However, extremely low tumor-derived DNA rates hinder cfDNA application.
View Article and Find Full Text PDFBackground: Tuberculous effusion varies from lymphocyte-dominant to neutrophilic effusion according to inflammation status. The criteria of adenosine deaminase (ADA) and lymphocyte/neutrophil (L/N) ratio have yet not been evaluated across different disease conditions.
Methods: Patients who conducted pleural fluid analysis from 2009 to 2019 at Asan Medical Center were included.
Background: Although acute exacerbation (AE) after treatment for lung cancer (LC) is a poor prognostic factor in patients with interstitial lung disease associated with lung cancer (ILD-LC), the risk of AE according to cancer treatment type remains unclear. Therefore, in the present study, we aimed to investigate the association between AE and treatment received for LC in patients with ILD-LC.
Methods: We conducted a retrospective study of patients with ILD-LC who had undergone treatment for LC between January 2018 and December 2022.
Background: Small cell lung cancer (SCLC) has an exceptionally poor prognosis; as most of the cases are initially diagnosed as extensive disease with hematogenous metastasis. Therefore, the early diagnosis of SCLC is very important and may improve its prognosis.
Methods: To investigate the feasibility of early diagnosis of SCLC, we examined exosomal microRNAs (miRNAs) present in serum obtained from patients with SCLC.
AXL is a member of TAM receptor family and has been highlighted as a potential target for cancer treatment. Accumulating evidence has uncovered the critical role of the AXL signaling pathway in tumor growth, metastasis, and resistance against anti-cancer drugs, as well as its association with cancer immune escape. However, the function of AXL as a manipulator of the immune system in the tumor microenvironment (TME) remains unclear.
View Article and Find Full Text PDFBackground: As the outcome of immunotherapy can be improved when concurrently or sequentially combined with cytotoxic chemotherapy or radiotherapy, we investigated the efficacy of immunotherapy maintenance following platinum-based chemotherapy in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (EGFR-TKI) failure.
Methods: In this prospective, open-label, single arm phase 2 trial, we enrolled patients aged 18 years or older with EGFR-mutant NSCLC, which progressed after first- or second-line EGFR-TKI. Patients received platinum-based chemotherapy followed by nivolumab maintenance therapy.
Background: Although bronchoscopic cryotherapy (BC) is a pragmatic modality for recanalization of central airway obstruction (CAO), the risk of complications, such as bleeding, remains a concern. This study aimed to present the clinical outcomes of BC and evaluate the factors associated with its complications.
Methods: In this retrospective study, we reviewed the medical records of patients who underwent BC for CAO at the Asan Medical Center, South Korea.
Background: Lung cancer is associated with significant psychological distress, including fear of progression (FoP). Because insomnia and depression are highly prevalent and associated with FoP, we examined the association between FoP, insomnia, and depression in cancer patients. Furthermore, we tested the mediation effect of cancer-related dysfunctional beliefs about sleep (C-DBS) on this association.
View Article and Find Full Text PDF